Literature DB >> 15750395

Evaluating the potential impact of vaginal microbicides to reduce the risk of acquiring HIV in female sex workers.

Robert J Smith1, Erin N Bodine, David P Wilson, Sally M Blower.   

Abstract

OBJECTIVES: The following questions were addressed: would the introduction of vaginal microbicides substantially reduce the risk of female sex workers (FSWs) acquiring HIV? Which factor would it be most important to maximize, microbicide efficacy or microbicide use? What level of microbicide efficacy and use would be necessary to counterbalance a possible reduction in condom use?
DESIGN: Mathematical modeling, with parameter estimations from available literature.
METHODS: Risk equations were developed and Monte Carlo simulations were performed to model a FSW's daily risk of HIV acquisition currently, and after, microbicide introduction. Uncertainty and sensitivity analyses were used as well as tornado plots for two ranges of microbicide efficacy (30-50%) and (50-80%). Risk was estimated for FSWs whose clients sometimes (10-50%) use condoms, and those whose clients never use condoms. An analytical threshold for which reducing condom use increases risk was estimated.
RESULTS: For both groups of FSWs, daily risk would decrease by approximately 17% or approximately 28% using 30-50% or 50-80% effective microbicides, respectively. Increasing microbicide use would have greater impact on reducing risk than increasing microbicide efficacy. The microbicide efficacy and usage required to ensure that 'condom replacement' does not increase a FSW's risk of acquiring HIV was calculated.
CONCLUSIONS: Microbicides could substantially reduce FSWs' risk of acquiring HIV; absolute decrease in risk would be greatest in high-prevalence regions. The public health impact of microbicides will depend upon usage and efficacy. Even if the microbicides that become available are only low-to-moderately effective, the probability that risk in FSWs will increase (due to replacing condoms with microbicides) is low.

Mesh:

Substances:

Year:  2005        PMID: 15750395     DOI: 10.1097/01.aids.0000161771.44276.92

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  16 in total

1.  In vitro activities of candidate microbicides against cell-associated HIV.

Authors:  Philippe Selhorst; Katrijn Grupping; Thomas Bourlet; Olivier Delézay; Kevin K Ariën; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

2.  Choice in HIV testing: the acceptability and anticipated use of a self-administered at-home oral HIV test among South Africans.

Authors:  Elizabeth A Kelvin; Sonia Cheruvillil; Stephanie Christian; Joanne E Mantell; Cecilia Milford; Letitia Rambally-Greener; Nzwakie Mosery; Ross Greener; Jennifer A Smit
Journal:  Afr J AIDS Res       Date:  2016-07       Impact factor: 1.300

3.  Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.

Authors:  Philippe Selhorst; Ana C Vazquez; Katty Terrazas-Aranda; Johan Michiels; Katleen Vereecken; Leo Heyndrickx; Jan Weber; Miguel E Quiñones-Mateu; Kevin K Ariën; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

4.  Potential impact of vaginal microbicides on HIV risk among women with primary heterosexual partners.

Authors:  James M McMahon; Kathleen M Morrow; Margaret Weeks; Dianne Morrison-Beedy; Amanda Coyle
Journal:  J Assoc Nurses AIDS Care       Date:  2010-06-18       Impact factor: 1.354

5.  Modeling the gender-specific impact of vaginal microbicides on HIV transmission.

Authors:  Dobromir T Dimitrov; Marie-Claude Boily; Rebecca F Baggaley; Benoit Masse
Journal:  J Theor Biol       Date:  2011-08-10       Impact factor: 2.691

Review 6.  Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis.

Authors:  Kimberly A Powers; Charles Poole; Audrey E Pettifor; Myron S Cohen
Journal:  Lancet Infect Dis       Date:  2008-08-04       Impact factor: 25.071

7.  Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection.

Authors:  Katty Terrazas-Aranda; Yven Van Herrewege; Daria Hazuda; Paul Lewi; Roberta Costi; Roberto Di Santo; Andrea Cara; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

8.  Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine.

Authors:  Urvi M Parikh; Charles Dobard; Sunita Sharma; Mian-er Cong; Hongwei Jia; Amy Martin; Chou-Pong Pau; Debra L Hanson; Patricia Guenthner; James Smith; Ellen Kersh; J Gerardo Garcia-Lerma; Francis J Novembre; Ron Otten; Thomas Folks; Walid Heneine
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

9.  Can we spend our way out of the AIDS epidemic? A world halting AIDS model.

Authors:  Robert J Smith; Jing Li; Richard Gordon; Jane M Heffernan
Journal:  BMC Public Health       Date:  2009-11-18       Impact factor: 3.295

10.  Intravaginal practices and microbicide acceptability in Papua New Guinea: implications for HIV prevention in a moderate-prevalence setting.

Authors:  Andrew Vallely; Lisa Fitzgerald; Voletta Fiya; Herick Aeno; Angela Kelly; Joyce Sauk; Martha Kupul; James Neo; John Millan; Peter Siba; John M Kaldor
Journal:  BMC Res Notes       Date:  2012-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.